pmh20180213_sc13ga.htm

0001437749-18-002451.txt : 20180214 0001437749-18-002451.hdr.sgml : 20180214 20180214100028 ACCESSION NUMBER: 0001437749-18-002451 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sun BioPharma, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88985 FILM NUMBER: 18608202 BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Herron Paul M. CENTRAL INDEX KEY: 0001652964 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 105 CYPRESS LAGOON COURT CITY: PONTE VEDRA BEACH STATE: FL ZIP: 32082 SC 13G/A 1 pmh20180213_sc13ga.htm SCHEDULE 13G/A pmh20180213_sc13ga.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Sun BioPharma, Inc.

^{(Name of Issuer)}

Common Stock, $0.001 par value per share

^{(Title of Class of Securities)}

86664M107

^{(CUSIP Number)}

December 31, 2017

^{(Date of Event Which Requires Filing of this Statement)}

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Page 1 of 5

CUSIP No. 86664M107

13G

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Paul M. Herron

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP^*

(a) ☐

(b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF

SOLE VOTING POWER

202,265

BENEFICIALLY

OWNED BY

SHARED VOTING POWER

41,486

EACH

REPORTING

PERSON

SOLE DISPOSITIVE POWER

202,265

WITH:

SHARED DISPOSITIVE POWER

41,486

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

243,751 SHARES

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES^*

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.3%

TYPE OF REPORTING PERSON^*

^*SEE INSTRUCTION BEFORE FILLING OUT!

Page 2 of 5

Item 1.

(a)

Name of Issuer

Sun BioPharma, Inc.

(b)

Address of Issuer's Principal Executive Offices

712 Vista Blvd., #305

Waconia, MN 55387

Item 2.

(a)

Name of Person Filing

Paul M. Herron

(b)

Address of Principal Business Office or, if none, Residence

105 Cypress Lagoon Court

Ponte Vedra Beach, Florida 32082

(c)

Citizenship

USA

(d)

Title of Class of Securities

Common Stock

(e)

CUSIP Number

86664M107

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

☐ Broker or dealer registered under section 15 of the Act.

(b)

☐ Bank as defined in section 3(a)(6) of the Act.

(c)

☐ Insurance company as defined in section 3(a)(19) of the Act.

(d)

☐ Investment company registered under section 8 of the Investment Company Act of 1940.

(e)

☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).

(f)

☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).

(g)

☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

(h)

☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

(i)

☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

(j)

☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(J).

Page 3 of 5

Item 4. Ownership

(a)

Amount Beneficially Owned

243,751 Shares

(b)

Percent of Class

6.3%

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote

202,265

(ii)

Shared power to vote or to direct the vote

41,486

(iii)

Sole power to dispose or to direct the disposition of

202,265

(iv)

Shared power to dispose or to direct the disposition of

41,486

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8.

Identification and Classification of Members of the Group

Not Applicable

Item 9.

Notice of Dissolution of Group

Not Applicable

Page 4 of 5

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth

in this statement is true, complete and correct.

	February 14, 2018
	Date /s/ Paul M. Herron
	Signature Paul M. Herron
	Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Page 5 of 5